Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Curr Treat Options Oncol. 2022 Feb 23;23(2):254–267. doi: 10.1007/s11864-022-00942-8

Table 2.

NGS platforms and targetable/prognostic genes for HNSCC

Platform Total genes tested HNSCC biomarker genes tested HNSCC targetable genes tested Approval
FoundationOne CDx 324 (SNVs, indels, CNAs, rearrangements, MSI, TMB, PD-L1) Yes Yes 2017
MSK-IMPACT 468 (SNVs, indels, MSI) Yes Yes 2017
NantHealth Omics Core 468 (SNVs, indels, TMB) Yes Yes 2019
Illumina TruSight Oncology 500 523 (SNVs, indels, MSI, TMB) Yes Yes 2019
Tempus xT Oncology 648 (SNVs, indels, CAN, rearrangements, MSI, TMB, RNA transcriptome) Yes Yes Pending

SNV single nucleotide variants, Indels insertions/deletions, CNA copy number alterations, MSI microsatellite instability, TMB tumor mutational burden